Humacyte Capital Surpluse from 2010 to 2024

HUMA Stock  USD 4.43  0.15  3.50%   
Humacyte's Capital Surpluse is increasing over the years with slightly volatile fluctuation. Capital Surpluse is expected to dwindle to about 397.4 M. From 2010 to 2024 Humacyte Capital Surpluse quarterly data regression line had arithmetic mean of  142,795,354 and r-squared of  0.55. View All Fundamentals
 
Capital Surpluse  
First Reported
2010-12-31
Previous Quarter
625 M
Current Value
397.4 M
Quarterly Volatility
242.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Humacyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Humacyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.7 M, Interest Expense of 1.1 M or Selling General Administrative of 21.1 M, as well as many indicators such as Price To Sales Ratio of 96.95, Dividend Yield of 0.0 or PTB Ratio of 22.77. Humacyte financial statements analysis is a perfect complement when working with Humacyte Valuation or Volatility modules.
  
Check out the analysis of Humacyte Correlation against competitors.
For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.

Latest Humacyte's Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Humacyte over the last few years. It is Humacyte's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Humacyte's overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Humacyte Capital Surpluse Regression Statistics

Arithmetic Mean142,795,354
Geometric Mean13,495,117
Coefficient Of Variation170.13
Mean Deviation204,182,587
Median3,579,954
Standard Deviation242,931,632
Sample Variance59015.8T
Range621.4M
R-Value0.74
Mean Square Error28370.2T
R-Squared0.55
Significance0
Slope40,417,855
Total Sum of Squares826220.9T

Humacyte Capital Surpluse History

2024397.4 M
2023625 M
2022543.5 M
2021536.7 M

About Humacyte Financial Statements

Humacyte stakeholders use historical fundamental indicators, such as Humacyte's Capital Surpluse, to determine how well the company is positioned to perform in the future. Although Humacyte investors may analyze each financial statement separately, they are all interrelated. For example, changes in Humacyte's assets and liabilities are reflected in the revenues and expenses on Humacyte's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Humacyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse625 M397.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Humacyte is a strong investment it is important to analyze Humacyte's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Humacyte's future performance. For an informed investment choice regarding Humacyte Stock, refer to the following important reports:
Check out the analysis of Humacyte Correlation against competitors.
For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.34)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.53)
Return On Equity
(8.51)
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.